Animal Study Confirms Results Of ChromaDex, Inc. Human Clinical Study On Weight Loss With Pterostilbene
IRVINE, Calif., Nov. 12, 2014 /PRNewswire/ -- A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex (OTCQX: CDXC), an innovative natural products company that manufactures a proprietary pterostilbene ingredient, pTeroPure®.
As outlined in an Oct. 28 press release, researchers involved with the newly published study, conducted by The University of Basque Country's (UDV/EHU) nutrition and obesity group in collaboration with the United States Department of Agriculture (USDA), observed in animal models that the administration of pterostilbene "reduces the build-up of body fat, which could reduce the risk of developing other diseases like diabetes."
In 2012, Irvine, Calif.-based ChromaDex, which provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, conducted human clinical trials that also demonstrated the effects of pterostilbene on weight loss.
USDA research chemist Agnes M. Rimando, a named collaborator on the Gomez-Zorita study, is one of the inventors of the USDA pterostilbene patents licensed by ChromaDex. The findings of the study were also recently outlined in an article on NUTRAingredients.com.
The new data from the Gomez-Zorita animal study is fully consistent with results achieved by ChromaDex in the Phase 2/3 clinical study of its pTeroPure® pterostilbene. The study demonstrated that participants taking pTeroPure® at 100 milligram per day lost 3.04 pounds at confidence interval of 94.45 percent (p=0.055). Although statistical significance is based at a 95 percent confidence interval, the data trended toward significance. The study also showed statistically significant results for pterostilbene's ability to lower blood pressure without any serious adverse side effects.
ChromaDex's patented pterostilbene branded as pTeroPure® -- was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. ChromaDex launched pTeroPure® in 2010 and today, more than 40 consumer products containing pTeroPure® are available in the marketplace.
In 2010, ChromaDex announced an exclusive worldwide license for all patent rights of pterostilbene with the University of Mississippi and the USDA Agricultural Research Service. In April 2014, a collaboration formed by the University of Mississippi's Division of Technology Management, the USDA Agricultural Research Service's Natural Products Utilization Research Unit and ChromaDex won a Federal Laboratory Consortium 2014 Excellence in Technology Transfer Award for their work developing pterostilbene.
Commenting on the recent study, Frank Jaksch, co-Founder and CEO of ChromaDex stated: "This recently published study further confirms there is a connection between pterostilbene and weight loss. With regard to the pterostilbene human study that we conducted in 2012, we were surprised with the significant trend in weight loss, considering it was only an eight-week study. Given the challenges of finding effective, science-backed weight loss ingredients, our pTeroPure® pterostilbene provides the market with an excellent solution."
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY, a caffeine-pTeroPure® cocrystal; and NIAGEN, its recently launched branded nicotinamide riboside, a potent NAD+ booster and novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Inquiries:
ChromaDex Company Contact:
Laura Kelly, Executive Assistant
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.